FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077671808> ?p ?o ?g. }

• W2077671808 endingPage "715" @default.
• W2077671808 startingPage "708" @default.
• W2077671808 abstract "Imexon [AOP99.0001 (4-imino-1,3-diazobicyclo[3. 1. 0]-hexan-2-one)] belongs to a novel class of promising anticancer agents that induce tumor apoptosis through oxidative stress. Clinical experience since the late 1960s has provided initial evidence for a clinical antitumor activity. Our open-label, multicenter phase I clinical trial was designed to further investigate the adverse event (AEs) profile and pharmacokinetics of AOP99.0001 in pretreated myeloma patients and collect initial data on the potential clinical efficacy in this indication. Thirty-six patients with relapsed or refractory myeloma, who had been pretreated with at least two lines of therapy earlier, were included. Imexon was applied intravenously on 5 consecutive days for 2 weeks (d1-5 and d8-12) for a 3-week cycle. The plasma half-life of AOP99.0001 and its active metabolite AOP99.0002 was found to be approximately 1.2 and 2.6 h, respectively. The mean duration of treatment with Imexon was 6.8 weeks in a dose range between 50 and 1000 mg/m2 without reaching dose-limiting toxicity. Drug-related AEs occurring with a frequency of greater than 10% were fatigue, nausea, constipation, headache, asthenia, anemia, thrombocytopenia, leukopenia and creatinine increase. A total of nine severe adverse events occurred in three patients. No mortality was encountered when patients were on treatment with Imexon. Preliminary antimyeloma efficacy of AOP99.0001 was observed with 1 minimal response, 12 (36%) stable disease responses, and all other evaluable patients had progressive disease. Remarkably, the patient with minimal response also experienced a complete clinical resolution of myeloma-associated polyneuropathy. Overall, Imexon was safe and well tolerated in the dose range investigated. Imexon showed minor clinical activity as a single agent in heavily pretreated myeloma patients. On account of its unique mechanism of action, favorable toxicity profile, initial clinical evidence for antimyeloma activity, and its known synergistic activity in combination with approved agents for myeloma treatment, AOP99.0001 is recommended for future clinical studies in combination regimens in multiple myeloma." @default.
• W2077671808 created "2016-06-24" @default.
• W2077671808 creator A5001068881 @default.
• W2077671808 creator A5019792676 @default.
• W2077671808 creator A5025908450 @default.
• W2077671808 creator A5028662013 @default.
• W2077671808 creator A5038644598 @default.
• W2077671808 creator A5046364210 @default.
• W2077671808 creator A5055916434 @default.
• W2077671808 creator A5080397055 @default.
• W2077671808 creator A5081311666 @default.
• W2077671808 creator A5084285813 @default.
• W2077671808 date "2010-08-01" @default.
• W2077671808 modified "2023-09-29" @default.
• W2077671808 title "Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma" @default.
• W2077671808 cites W2008714118 @default.
• W2077671808 cites W2012843756 @default.
• W2077671808 cites W2015112307 @default.
• W2077671808 cites W2018276670 @default.
• W2077671808 cites W2066800926 @default.
• W2077671808 cites W2074829071 @default.
• W2077671808 cites W2075520012 @default.
• W2077671808 cites W2078075798 @default.
• W2077671808 cites W2088834215 @default.
• W2077671808 cites W2090912466 @default.
• W2077671808 cites W2159013865 @default.
• W2077671808 cites W2327154562 @default.
• W2077671808 doi "https://doi.org/10.1097/cad.0b013e32833b975b" @default.
• W2077671808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20571355" @default.
• W2077671808 hasPublicationYear "2010" @default.
• W2077671808 type Work @default.
• W2077671808 sameAs 2077671808 @default.
• W2077671808 citedByCount "7" @default.
• W2077671808 countsByYear W20776718082012 @default.
• W2077671808 countsByYear W20776718082014 @default.
• W2077671808 countsByYear W20776718082018 @default.
• W2077671808 countsByYear W20776718082021 @default.
• W2077671808 crossrefType "journal-article" @default.
• W2077671808 hasAuthorship W2077671808A5001068881 @default.
• W2077671808 hasAuthorship W2077671808A5019792676 @default.
• W2077671808 hasAuthorship W2077671808A5025908450 @default.
• W2077671808 hasAuthorship W2077671808A5028662013 @default.
• W2077671808 hasAuthorship W2077671808A5038644598 @default.
• W2077671808 hasAuthorship W2077671808A5046364210 @default.
• W2077671808 hasAuthorship W2077671808A5055916434 @default.
• W2077671808 hasAuthorship W2077671808A5080397055 @default.
• W2077671808 hasAuthorship W2077671808A5081311666 @default.
• W2077671808 hasAuthorship W2077671808A5084285813 @default.
• W2077671808 hasConcept C112705442 @default.
• W2077671808 hasConcept C121332964 @default.
• W2077671808 hasConcept C126322002 @default.
• W2077671808 hasConcept C142424586 @default.
• W2077671808 hasConcept C197934379 @default.
• W2077671808 hasConcept C2776364478 @default.
• W2077671808 hasConcept C2776694085 @default.
• W2077671808 hasConcept C2777063308 @default.
• W2077671808 hasConcept C2778248108 @default.
• W2077671808 hasConcept C2778822529 @default.
• W2077671808 hasConcept C2780873365 @default.
• W2077671808 hasConcept C29730261 @default.
• W2077671808 hasConcept C31760486 @default.
• W2077671808 hasConcept C71924100 @default.
• W2077671808 hasConcept C87355193 @default.
• W2077671808 hasConcept C90924648 @default.
• W2077671808 hasConceptScore W2077671808C112705442 @default.
• W2077671808 hasConceptScore W2077671808C121332964 @default.
• W2077671808 hasConceptScore W2077671808C126322002 @default.
• W2077671808 hasConceptScore W2077671808C142424586 @default.
• W2077671808 hasConceptScore W2077671808C197934379 @default.
• W2077671808 hasConceptScore W2077671808C2776364478 @default.
• W2077671808 hasConceptScore W2077671808C2776694085 @default.
• W2077671808 hasConceptScore W2077671808C2777063308 @default.
• W2077671808 hasConceptScore W2077671808C2778248108 @default.
• W2077671808 hasConceptScore W2077671808C2778822529 @default.
• W2077671808 hasConceptScore W2077671808C2780873365 @default.
• W2077671808 hasConceptScore W2077671808C29730261 @default.
• W2077671808 hasConceptScore W2077671808C31760486 @default.
• W2077671808 hasConceptScore W2077671808C71924100 @default.
• W2077671808 hasConceptScore W2077671808C87355193 @default.
• W2077671808 hasConceptScore W2077671808C90924648 @default.
• W2077671808 hasIssue "7" @default.
• W2077671808 hasLocation W20776718081 @default.
• W2077671808 hasLocation W20776718082 @default.
• W2077671808 hasOpenAccess W2077671808 @default.
• W2077671808 hasPrimaryLocation W20776718081 @default.
• W2077671808 hasRelatedWork W1981507940 @default.
• W2077671808 hasRelatedWork W1991102770 @default.
• W2077671808 hasRelatedWork W1999706042 @default.
• W2077671808 hasRelatedWork W2085996089 @default.
• W2077671808 hasRelatedWork W2135788809 @default.
• W2077671808 hasRelatedWork W2364106504 @default.
• W2077671808 hasRelatedWork W2378088005 @default.
• W2077671808 hasRelatedWork W2401101517 @default.
• W2077671808 hasRelatedWork W2409812054 @default.
• W2077671808 hasRelatedWork W2519997684 @default.
• W2077671808 hasVolume "21" @default.
• W2077671808 isParatext "false" @default.
• W2077671808 isRetracted "false" @default.

• next